Premium
P3‐023: CSF biomarkers of Alzheimer's disease: An algorithm for interpretation of neurochemical dementia diagnostics analysis
Author(s) -
Lewczuk Piotr,
Zimmermann Ruediger,
Wiltfang Jens,
Kornhuber Johannes
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.04.1200
Subject(s) - neurochemical , dementia , neuropsychology , cerebrospinal fluid , disease , categorization , medicine , interpretation (philosophy) , psychology , computer science , neuroscience , pathology , bioinformatics , artificial intelligence , psychiatry , cognition , biology , programming language
tau and amyloid-b 1-42 (Ab 1-42) in patients with AD compared to controls. Methods: Serum and CSF samples from patients referred to the memory clinic at the Copenhagen University Hospital were obtained during the period 2004-2005. The AD patients (n 1⁄4 26) fulfilled the NINCDS/ADRDA criteria for AD and the control group consisted of 42 patients with clinically confirmed non-AD neurodegenerative disorders. CSF markers were analysed using ELISA, SHBG was analysed using an immunofluoroimmunometric assay (AutoDELFIA) and the androgens were measured using ether extraction, liquid chromatography and radio immunoassay. Results: The levels of totaltau and p-tau differed significantly in AD patients compared to the control group. Ab 1-42 did not discriminate the two groups. None of the sex hormones differed significantly between AD patients and controls. Also, there was no statistically significant correlation between the AD CSF markers and sex hormone levels. However, when men and women were analysed separately, a statistically significant correlation was found between age, DHEAS serum level and AD diagnosis in men, but not in women. In particular, the group of men below the age of 65 had elevated DHEAS levels compared to age-matched control patients. Conclusions: We found no statistically significant differences between the groups or correlations with the CSF AD biomarkers except for elevated DHEAS serum levels in male subjects below the age of 65. The results warrant exploration in larger materials using more exact methods for steroid measurement such as tandem mass spectrometry and looking at other adrenal parameters.